Urogen Pharma Ltd (URGN) is around the top of the Biotechnology industry according to InvestorsObserver. URGN received an overall rating of 67, which means that it scores higher than 67 percent of all stocks. Urogen Pharma Ltd also achieved a score of 81 in the Biotechnology industry, putting it above 81 percent of Biotechnology stocks. Biotechnology is ranked 18 out of the 148 industries.
URGN has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on URGN!
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.
What's Happening With Urogen Pharma Ltd Stock Today?
Urogen Pharma Ltd (URGN) stock is higher by 1.67% while the S&P 500 is down -0.66% as of 11:59 AM on Friday, Mar 15. URGN is up $0.24 from the previous closing price of $14.33 on volume of 154,879 shares. Over the past year the S&P 500 has gained 29.19% while URGN is up 56.16%. URGN lost -$4.25 per share the over the last 12 months.
Click Here to get the full Stock Report for Urogen Pharma Ltd stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
